Rather than talking to you about the usual SARM’s that we deal with on gurupeptides.com, today we’re going to spend a little time getting our readers and customers familiar with a substance that is already being marketed publicly. Approved for manufacture and sale by all the major government entities that usually cause an issue, Flibanserin is marketed under the trade name Addyi.
Addyi is a prescription medication created targeting pre-menopausal women that are struggling with sexual desire. Hypoactive sexual desire disorder, or HSDD, is the official name for somebody struggling with sexual dysfunction long before their time. Addyi was created for those individuals who suffer from HSDD and don’t have the healthy amount of sexual desire, as diagnosed by a physician.
How Flibanserin Works
Flibanserin is primarily an agonist in the frontal cortex of the brain, as well as the raphe dorsalis. This holds particularly true in females. Secondarily, it is a partial agonist in the hippocampus portion of the brain. Increasing brain activity in these areas naturally leads to an increase in sexual desire as well as drive and motivation. Flibanserin has been proven to regulate levels of dopamine and serotonin to help find that sexual desire sweet spot in women.
Side Effects of Flibanserin Supplementation
Thankfully the side effects of Flibanserin supplementation are relatively mild. There isn’t anything life threatening to worry about. The leading side effects tend to exist in women but some men who have experimented with Flibanserin have experienced similar side effects.
- Dizziness – The number one side effect reported by users. Dizziness seems to occur in almost half of the people who use. To counteract it, most people just take their dose right before bed. By the time you wake up, the effects have worn off.
- Nausea – The second most frequent side effect reported. Not surprising since dizziness can cause nausea. The upset stomach feeling never lasts very long.
- Drowsiness – Not as common as the first two, drowsiness is occasionally reported.
It’s suggested that when you supplement with Flibanserin, you dose right before bed at night. Nearly all patients prescribed Addyi are instructed to take their meds with a glass of water before bed so that they don’t feel any of the side effects.
Nobody has been able to prove alternate use cases for Flibanserin. That doesn’t mean there aren’t any. Like with most things in the world of medicine, it’s a matter of research. For example, in one particular study completed by various departments from various accredited universities, Flibanserin was found to cause a fluctuation in weight for test subjects. Women were found to actually have a little more energy and their bodies were able to leverage that energy to promote a health metabolic rate. This rate was even more positively affected when you took the increase in sex into consideration. There is an assumption that we could leverage Flibanserin to improve energy levels and weight loss in pre-menopausal women that are suffering from disorders or chemical imbalances that decrease desired levels of energy.
1 Faina Gelman and Jessica Atrio. “Flibanserin for hypoactive sexual desire disorder: place in therapy.” Therapeutic Advances in Chronic Disease: SAGE Journals., U.S. National Library of Medicine, Jan. 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5298357/.
2 Jaspers, L, et al. “Efficacy and Safety of Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Women: A Systematic Review and Meta-Analysis.” Current Neurology and Neuroscience Reports., U.S. National Library of Medicine, Apr. 2016, www.ncbi.nlm.nih.gov/pubmed/26927498.
3 Susan G. Kornstein, MD, James A. Simon, MD, Stuart C. Apfel, MD, James Yuan, MD, PhD, MBA, Krista A. Barbour, PhD, MPH, and Robert Kissling, MD. “Effect of Flibanserin Treatment on Body Weight in Premenopausal and Postmenopausal Women with Hypoactive Sexual Desire Disorder: A Post Hoc Analysis.” Journal of Women’s Health., U.S. National Library of Medicine, Nov. 2017, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5695746/.